ICT 2025
29th International Congress on Thrombosis
Porto, Portugal
6-8 November 2025
Sheraton Hotel
ICT 2025 Welcome
ICT 2025 is a three-days congress entirely dedicated to the study of thrombotic diseases in various aspects. We will discuss the topic of thrombosis and thrombotic disorders from the bench to the bedside. An excellent scientific program served by a faculty of outstanding scientists and clinicians working in the field, is a great motivation to invite you all to come to Porto, Portugal.
Dear colleagues
I´m pleased to welcome you to the 29th International International Congress on Thrombosis 2025 (ICT 2025), the biannual congress of the European and Mediterranean League Against Thrombotic Diseases (EMLTD), to be held in Porto, Portugal, on 6-8 November, 2025.
ICT 2025 is a three-days congress entirely dedicated to the study of thrombotic diseases in various aspects. We will discuss the topic of thrombosis and thrombotic disorders from the bench to the bedside. An excellent scientific program served by a faculty of outstanding scientists and clinicians working in the field, is a great motivation to invite you all to come to Porto.
Main lectures, symposia, sponsored sessions, case-based sessions, and a large space dedicated to poster´s exhibition, will be at your disposal. Specially thinking on the young fellows, students and PhD students, moments of networking will be provided where you are invited to meet with colleagues and friends.
Time is running out and you need to select the research you want to share and the results you can discuss. We expect a large number of clinicians with different backgrounds. Cardiologists, neurologists, oncologists, angiologists, internists, diabetologists, general practitioners, hematologists, nephrologists, everyone is welcome to attend ICT2025. In addition to clinicians, basic and translational scientists, everyone will find good reasons to participate.
Finally let me remind you Porto is a wonderful city with a lot of opportunities to attract visitors, an extra motivation to participate in our congress.
We will do our best making this congress as an exciting scientific experience you will never forget.
Porto, 19th February 2025
João Morais
Chairperson
President EMLTD
Luciana Gonçalves
Chairperson
Sponsorship
Scientific Supporters
Silver Sponsor
Bronze Sponsors
Join us!
ICT 2025 is both a scientific and educational meeting. It is a unique opportunity to learn more about the multidisciplinary and translational approaches of thrombosis. The conference provides a natural platform for professionals to learn, exchange and disseminate best practices for patient’s benefit. Discuss innovations, therapies and applications improving patient care: a unique opportunity for wide-reaching exchange. Join our scientific programme with a Satellite Symposium and showcase your company’s solutions with an exhibition located in a prime position.
For more information, please check our Exhibitor’s Manual
PROGRAMME
- 6 November
- MEETING ROOM A
14h15 | 14h30 Welcome address
14h30 | 16h00 Cancer Associated Thrombosis – I
- Cancer-associated thrombosis – epidemiology | Sérgio Barroso
- Cancer-associated thrombosis and thrombocytopenia - Therapeutic challenge | Gregor Tratar
- VTE and mortality in hematological malignancies | Ismail Elalamy
- Treatment of CAT: role of Factor XI inhibitors | Filipe Gonçalves
16h00 | 16h30 Coffee break and poster exhibition
16h30 | 18h00 Thrombophilias, genetic disorders
- Update on inherited thrombophilias | Francisco Araújo
- Adquired thrombophilias: the other side of the spectrum | Carlos Vasconcelos
- Coagulation and fertility: the role of thrombophilia | Filipa Bargado
- Can DOACs play a role in inhererited thrombophilia? | Ileana Desormais
- Thrombophilia: from phenotype to genotype | Ismail Elalamy
18h00 | 18h30 Moderated Posters
- Primary Thromboprophylaxis and OnkoTEV Score in Pancreatic Cancer: Real-World Evidence from a Portuguese Cohort | Inês Dunões
- Early Cardiorenal Risk Factors in Patients with Preserved eGFR: Integration of Vascular and Renal Biomarkers | Ruslan Najaf Najafov
- Impact of dextran sulfate and exogenous antithrombin on anti-Xa levels in patients receiving low-molecular-weight heparin | Tamara Rojnik
- Agreement between classical and two automated platelet aggregometers in the assessment of response to antiplatelet therapy | Tamara Rojnik
- Cost-effective strategy for the optimization of ADAMTS13 activity testing in Croatia | Désirée Coen Herak
- MEETING ROOM B
14h30 | 16h00 Mechanisms of thrombosis
- Visceral adiposity and increased thrombotic risk. Is the next therapeutic target? | Teresa Padró
- Platelets in thrombosis and inflammation following trauma injuries | Ana Bronic
- Clonal hematopoiesis and the risk of thrombosis | Elif G. Umit
- Innate immunity and neutrophil’s role in atherothrombosis | Dimitrios Sagris
16h00 | 16h30 Coffee break and poster exhibition
16h30 | 18h00 From lytics up to mechanical thrombectomy
- Mechanical thrombectomy vs catheter-directed thrombolysis for venous thromboembolism | Sílvio Leal
- Modern treatment of pulmonary embolism in high risk patients | Rita Calé
- Thrombolysis in acute ischemic stroke. An update | Hrvoje Budincevic
- Mechanical thrombectomy with or without lytics in acute ischemic stroke | Ângelo Carneiro
- Composition of stroke thrombi | Simon de Meyer
18h00 | 18h30 Moderated Posters
- Platelet Transfusions to Support Anticoagulation Management in Thrombocytopenic Hemato-Oncologic Patients: A Retrospective Analysis | Miguel Lima Basto
- Prevalence and clinical relevance of IgA anticardiolipin and IgA anti-ß2 glycoprotein I antiphospholipid antibodies in splanchnic vein thrombosis | Mariem Cheikhrouhou
- Early rotem measurements guide timely hemostatic rotem measurements guide timely hemostatic interventions: Correlation of A5 and A10 with MCF | Yosr Kalboussi
- The role of coagulation factors VIII, IX and XI in pregnancy loss: A case-control study | Sarah Boughanmi
- Clinical profile of HIT and correlation with the 4T score | Yasmine Ben Salem
- 7 November
- MEETING ROOM A
08h30 | 10h00 Moderated posters
Case-based session
-
Early bioprosthetic valve thrombosis prompted by endocrine disease | Catarina Gonçalves Coelho
- Bilateral Thalamic and Midbrain Infarction Due to Artery of Percheron Occlusion: A Case Report | Tiago Constantino
- Listening to the Heart: Frank’s Sign as a Non-Invasive Indicator of Coronary Artery Disease | Beatriz Vargas Andrade
- Unmasking Radiation-Induced Cardiac Injury: Acute Coronary Syndrome During Cancer Treatment | Beatriz Vargas Andrade
- Haemorrhagic stroke, a pulmonary headache | Nuno Oliveira
- Recombinant activated factor VII as salvage treatment in life-threatening postpartum haemorrhage | Inês Domingues Moreira
- Factor V Leiden and Pregnancy Loss: A Clinical Case Report | Raquel Serra Patrão
- Post-surgical hemorrhage in senile entropion due to factor XIII deficiency | María Victoria Cuevas
- When Coagulation Unmasks Cancer: Disseminated Intravascular Coagulation as the First Clue to Gastric Adenocarcinoma | Mário Oliveira
- Clinical Case Report: Peripartum Anticoagulation Management in Pregnant Women with a Mechanical Aortic Valve | João Pedro Carvalho
- PEG-asparaginase–related Venous Thromboembolism in Adult Acute Lymphoblastic Leukemia: A Case of Coexisting Thrombotic and Bleeding Risks | Maria Teresa Vieira
- Dual Presence of Anti-Factor VIII Antibody and Lupus Anticoagulant: A Rare and Confounding Case | Dhaha Yosra
- Protein S Deficiency and Antiphospholipid Syndrome: Are They Related? | Inês Soares dos Santos
- Temporary mechanic aortic valve dysfunction – a clinical dilemma to solve | Catarina Gonçalves Coelho
- Simultaneous Onset of Stroke and STEMI: Diagnostic and Therapeutic Dilemmas in Emergency Medicine | Ines Vaide
10h00 | 11h00 Joint Session EMLTD - Portuguese Association of Thrombosis and Haemostasis
Thrombotic diseases in childs and young adults
- Pediatric thrombosis: Why, when | Teresa Sevivas
- Thrombosis in pediatric ICU patients | Heleen van Ommen
- Use of DOACs in pediatric patients | Lídia Costa
- Thromboprophylaxis in children with cancer | Nuno Farinha
11h00 | 11h30 Coffee break and poster exhibition
11h30 | 13h00 Joint Session EMLTD - Portuguese Association of Thrombosis and Haemostasis
Women, hormones and pregnancy
-
Thrombosis in pregnancy: mechanisms and underlying risk factors | Ana Luísa Areia
- Thrombophilia testing and thromboprophylaxis in the obstetric setting | Sofia Teixeira
- Anticoagulation therapy in pregnancy. Managing risks | Diana Cibele Gonçalves
- Hormone therapy and thrombosis | Maria João Carvalho
13h00 | 14h00 Lunch time and sponsored sessions
14h00 | 14h30 Keynote lecture
14h30 | 16h00 Cancer associated thrombosis – II
-
Endothelial dysfunction in cancer | Inês Guerra de Melo
- Approach to tumoral thrombosis | Joana Liz Pimenta
- Cancer-associated thrombosis and immune checkpoint inhibitors: update | Miguel Barbosa
- Genetic markers of Cancer - associated thrombosis | Valéria Tavares
- Thrombotic risk versus haemorrhagic risk – strategies | Andrés Muñoz Martín
16h00 | 16h30 Coffee break and poster exhibition
16h30 | 17h30 Thrombotic risk in platelet disorders
-
Immune thrombocytopenic purpura | Eva Mingot
- Rapid determination of ADAMTS13 – implication for the prompt diagnosis of TTP | Désirée Coen Herak
- Treatment options of immune and congenital TTP | Marijo Vodanović
- Platelet function testing: update and future directions
17h30 EMLTD General Assembly
- MEETING ROOM B
08h30 | 10h00 Oral Communications
- From PE to CTEPH: Still Lost in Translation. | Lourenço Aguiar
- Gene Expression Profiles Linking ADAM22 and CTNNB1 Downregulation to Increased Atherothrombotic Complications in Familial Hypercholesterolemia | Rafael Escate
- Thromboprophylaxis in Ambulatory Cancer Patients: Concordance Between Khorana Score and Clinical Practice | Pedro Lima Lopes
- Is There a Cure for CTEPH? Long-Term Functional and Hemodynamic Outcomes After PEA and BPA | Rita Calé Theotónio
- Altered HDL Proteomic Profile Reflects Enhanced Atherothrombotic Risk in Familial Hypercholesterolemia | Paula Cabré
- Sex-Dependent Variations in Platelet Tissue Factor Expression in Familial Hypercholesterolemia: Implications for Thrombotic Risk | Victoria Santisteban
- Antiplatelet therapy and prognosis in patients with spontaneous coronary artery dissection: a single-center cohort study | Carla Oliveira Ferreira
- Thrombotic Events after Prothrombin Complex Administration in Chronic Liver Disease and Cirrhosis’ Patients: A Tertiary Care Hospital Retrospective Study | Inês Domingues Moreira
- ROTEM® Meets Xabans: Tracking Anticoagulation in Real Time | Dhaha Yosra
10h00 | 11h00 Laboratory monitoring of haemostasis
-
Inter-laboratory comparability of anti-Xa for measuring blood concentrations of oral anti-Xa inhibitors | Mojca Božič Mijovski
- Global coagulation assays: is there a role in thrombosis risk evaluation | Klaus Gorlinger
- Thrombin generation assay: from resarch to clinical use | Désirée Coen Herak
- Lupus Anticoagulant: a puzzling laboratory test | Vittorio Pengo
11h00 | 11h30 Coffee break and poster exhibition
11h30 | 13h00 Bleeding and hemorrhagic disorders
- Anemia and bleeding issues in women | Lídia Costa
- Novel treatments of bleeding disorders-are we increasing the risk of thrombosis? | Gilli Kenet
- Antithrombotic therapy in patients at high bleeding risk | Erik Grove
- High bleeding risk definition | Moa Simonsson
13h00 | 14h00 Lunch time and sponsored sessions
14h00 | 14h30 Keynote lecture: Cancer-associated thrombosis: pathophysiology complexity | Rui Medeiros
14h30 | 16h00 News on antithrombotic therapy - I
-
Factor XI inhibitors – premises, promises and challenges | Juan Tamargo
- Cardiogenic shock, a permanent challenge to antithrombotic therapy | Jorge Ferreira
- Perioperative management of anticoagulant and antiplatelet therapy | Luciana Gonçalves
- How to handle high bleeding risk patients in the cath lab | Andrea Rubboli
16h00 | 16h30 Coffee break and poster exhibition
16h30 | 17h30 Atrial fibrillation a good model
to test antithrombotic strategies
-
How to assess thromboembolic risk beyond classical risk scores? | Ana Teresa Timóteo
- Role of DOACs in patients with asymptomatic subclinical AF detected by device | Daniel Caldeira
- Antithrombotic treatment in ACS with coexisting atrial fibrillation | Raffaele De Caterina
- How to organize an integrative clinical patient care pathway | Jose Ramon Juanatey
- 8 November
- MEETING ROOM A
08h30 | 09h30 Oral Communications
- Spontaneous haematomas associated with enoxaparin: A retrospective study | Liliana Sousa Nanji
- Venous Thromboembolism and Cancer: Hospital Characterization and VTE as a Potential Sentinel Event | Gil Rodrigues Magalhães
- Heparin-induced thrombocytopenia managed with a direct oral anticoagulant: A case report | Dhaha Yosra
- Activated charcoal neutralizes Xaban interference in vitro: A practical and efficient approach | Dhaha Yosra
- Pretreatment with P2Y12 inhibitors in STEMI patients referred to primary PCI – insights from a national registry | Pedro Sousa Mateus
09h30 | 10h00 Advances in cerebral venous thrombosis | Diana Aguiar de Sousa
10h00 | 11h00 DVT and pulmonary embolism
-
Diagnosis and treatment of splanchnic vein thrombosis | Walter Ageno
- Prolonged treatment after VTE – which drugs to which patients? | Joana Martins Pimenta
- ACT for thrombosis of unusual sites - to DO(AC) or not to DO(AC) | Omri Cohen
- Thrombosis in multiple myeloma patients (use of PRISM SCORE) | Anna Falanga
11h00 | 11h30 Coffee break and poster exhibition
11h30 | 13h00 Joint Session EMLTD - Portuguese Society of Cardiology
Old and new issues in Thrombocardiology
-
Which is the optimal duration of dual antiplatelet therapy after ACS | João Morais
- Clinical effects of twice - versus once-daily low-dose aspirin | Bianca Rocca
- Antithrombotic management after non-coronary interventions | Eduardo Oliveira
- Prosthetic heart valves. What changed in terms of thrombotis risk? | Cristina Gavina
- Antithrombotic drugs for ACS in women | Cláudia Moreira Jorge
13h00 | 14h00 Lunch time and sponsored sessions
14h00 | 14h30 Keynote lecture: Obesity, inflammation and thrombosis
14h30 | 16h00 News on antithrombotic therapy - II
-
Novel antiplatelet and anticoagulant drugs under clinical development | José Luis Ferreiro
- Is there still room for oral anticoagulants after ESUS in sinus rhythm? | João Sargento Freitas
- Aspirin for primary cardiovascular prevention. Is there still a role? | Nikolaos Kakaletsis
- Bentracimab significantly restored platelet function in patients taking Ticagrelor
- Antithrombotic strategies for patients with peripheral artery disease | Joana Ferreira
16h00 Closing Session
- MEETING ROOM B
08h30 | 09h30 Oral Communications
- Evaluation of pretest clinical score (4Ts) for diagnosis of heparin-induced thrombocytopenia - A retrospective study of a tertiary hospital | Susana Reis da Silva
- Outpatients over 75 with a first venous thromboembolic event: a prospective observational study of therapeutic management after the acute phase in the first 12 months (SOCRATE STUDY). | Francesca Curri
- Implementation of a Thrombotic Thrombocytopenic Purpura Management Protocol in a Tertiary Hospital | Mónica Baptista Lopes
- D-Dimer Testing in the Emergency Department: Low Specificity and High Imaging Burden in Older and Comorbid Patients | Susana Reis da Silva
09h30 | 10h00 Keynote lecture: Thrombosis, translational medicine and biomarkers research
10h30 | 11h00 Immunothrombosis: molecular aspects and perspectives for therapy
-
Complement and coagulation. Strangers or partners in crime? | Georgia Kaiafa
- Trauma and sepsis induced coagulopathy | Ana Bronic
- How to balance bleeding and thrombosis in patients on LVAD | Roberto Roncon
- Anti PF4 antibodies: not only VITT and HIT | Yves Gruel
11h00 | 11h30 Coffee break and poster exhibition
11h30 | 13h00 Topics to think, topics to react
-
Antiphospholipid syndrome. A continuous challenge to the clinicians | Ester Ferreira
- The role of NETs in atherothrombosis | Alexandros Tselepis
- D-dimer assay: over-testing in VTE? | Christos Savopoulos
- Haemostasis and anticoagulation in progression of kidney disease | Joaquim Calado
13h00 | 14h00 Lunch time and sponsored sessions
14h00 | 14h30 Keynote lecture: Virus, vaccines and haemostasis: looking through the evidence | Yves Gruel
14h30 | 16h00 The role of Artificial Intelligence (AI) and machine learning
-
The AI co-pilot: a new ally against thrombotic diseases | Daniel Ferreira
- The role of Artificial Intelligence (AI) and machine learning in thrombosis | Tiago Taveira
- AI in atrial fibrillation: from early detection to precision therapy | Francisco Moscoso Costa
- AI applied to the diagnosis of coronary artery disease | Miguel Nobre Menezes
Comittees
Organising Committee
João Morais, PT
ICT 2025 Chairperson
Luciana Gonçalves, PT
ICT 2025 Chairperson
Daniel Caldeira, PT
Filipe Gonçalves, PT
Francisco Araújo, PT
Miguel Barbosa, PT
Silvia Monteiro, PT
Teresa Padró, ES
Scientific Committee
Alexandros Tselepis, GR
Ana Bronic, CR
Anna Falanga, IT
Bianca Rocca, IT
Bruna Gigante, SE
Cristina Gavina, PT
Désirée Coen Herak, HR
Diana Aguiar Sousa, PT
Eduardo Oliveira, PT
Gemma Vilhaur, SP
Georgia Kaiafa, GR
Gili Kenet, IL
Gregor Tratar, SI
Hrvoje Budincevic, HR
Ileana Desormais, FR
Ismail Elalamy, FR
Joana Liz Pimenta, PT
José Ramon Juanetey, ES
Juan Tamargo, ES
Lina Badimon, SP
Mojca Bozic, SI
Rafaelle De Caterina, IT
Ricardo Fontes-Carvalho, PT
Rui Medeiros, PT
Sérgio Barroso, PT
Teresa Padró, ES
Ton Lisman, NL
Vittorio Pengo, IT
Call for Abstracts
- KEY DATES
1 March 2025 | Abstract submission open
17 October 2025 (23h59 WEST) | Abstract submission deadline
18-23 October 2025 September 2025 | Review and evaluation
24 October 2025 | Notification of acceptance of abstracts
30 October 2025 | Presenting author registration and payment deadline
6-8 November 2025 | ICT 2025 Meeting
Accepted Abstracts will be published in the journal Thrombosis & Haemostasis.
- GUIDELINES
Abstracts must be original and must not have been published or presented at any other meeting prior to ICT 2025. Abstracts of unfinished research will not be evaluated. Abstracts stating "data will be discussed in the presentation" will not be accepted.
Submissions for oral communications and posters will be accepted. The final presentation method will be decided by the organising committee. During the submission it should be indicated if the authors only accept one or both forms of presentation.
The abstract body must not include any indication of the personal details of the authors. Avoid also reference to institutions, locations, or funding sources.
Abstracts must be submitted using exclusively the online abstract submission form you will find on the website. Abstracts submitted by email or fax will not be accepted. Abstracts received after the deadline will not be considered. The presenting author is responsible to ensure that all co-authors are aware of the content of the abstract before submission.
The presenting author must be the contact author in the submission form, and must be listed in the list of authors. Each presenting author can submit a maximum of 2 abstracts, but the same research cannot be submitted twice, even with a different title. The presenting author must register for the congress before 5 October 2025 to ensure the abstract is included in the programme.
- ABSTRACT TEXT
It must not exceed 500 words and must be written in English. Please do not leave blank lines to separate paragraphs. Special characters and symbols are accepted in the abstract except in the title. We suggest typing the text in a Word processing programme in a common font and copy-paste it into the corresponding field.
- ABSTRACT STRUCTURE
• Background
• Material and methods
• Results
• Conclusions
- IMAGES AND TABLES
Image files and tables saved as images will be accepted. Images must be uploaded in the submission form as attach of the abstract. The maximum number of files uploaded will be 3, each not exceeding 20 MB.
- HOW TO USE THE ONLINE ABSTRACT SUBMISSION FORM
Please click here to access the abstract submission platform and follow the step-by-step instructions indicated below:
1. A login will be required. To receive your login please click on “New registration”.
2. In the “New registration” option please fill in your username and create your own password and click on “Submit”.
3. Please use the data created and click on “Login” to access the platform and to submit your abstract.
4. Please identify the event “ICT 2025” and select the option “Submit” in the column corresponding to the Abstract Submission.
5. Consult the “Guidelines” and click on “Next”.
6. Start editing your abstract and click on “Continue” to conclude the submission.
7. On the last menu you will have two options: save a “Draft” or submit the “Final version”. Saving a draft will allow you to revise it after or to make changes. Please note that all changes must be made and submitted by 7 September 2025 (23h59 WEST). By saving the “Final version” your abstract will be locked to be reviewed by the Scientific and Organising Committees. If you intend to make any changes after saving it as “Final version” please contact the secretariat to secretariado@factorchave.pt. After 7 September 2025 no changes will be allowed.
8. After submitting the “Final version” you will receive an automatic e-mail confirming the submission.
9. Please note that the registration that you made previously to access the abstract platform does not validate your registration in the congress.
For any further information related to abstract submission please contact the Secretariat by email: secretariado@factorchave.pt.
- CHANGES AND CORRECTIONS
Once the abstract is submitted, it is possible to make corrections to the content or information (such as authors list and details, theme, conclusion(s) etc.) but always prior to the abstract’s deadline. To correct your abstract, you must contact the Secretariat. Please note that modifications of your abstract are not possible after the deadline. In the case of errors in your abstract discovered after the deadline, you may indicate the correction in your presentation. If you want to withdraw an abstract already submitted, please notify us as quickly as possible at secretariado@factorchave.pt stating the title and number of the abstract to be withdrawn.
- EVALUATION AND ACCEPTANCE
The final selection will be made by the Scientific and Organising Committees which will determine the acceptance or rejection of each abstract. All abstract submitters will be notified by e-mail by 26 September 2025, about the outcome of the review and selection process. Please ensure that the email provided is accurate as all correspondence will be sent via email. If the abstract is accepted, further instructions will be provided at the time of the results announcement.
How to get there
- Sheraton Porto Hotel & Spa
Address
R. do Ten. Valadim 146, 4100-476 Porto
Phone
City of Porto
City of Porto also known by the Portuguese people as "Invicta", Classified by UNESCO as a World Heritage Site, Porto also stands out for its unique gastronomy and hospitality of its people.
Here are some usefull links to learn more:
Sponsors
AVAILABLE SOON
